Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 23:23 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT05467514 · Registry updated: 2023-03-02

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: David Sanchez Garcia
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-07-01. Completion: 2023-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Centro Médico Nacional del Noreste Hospital de Especialidades UMAE 25
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of LY3537021 in Healthy Participants

ClinicalTrials.gov · NCT05444569 · Registry updated: 2023-03-01

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: Singapore
Registry dates and results: Start: 2022-08-08. Completion: 2023-02-24 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY3537021 (drug)
Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT04657939 · Registry updated: 2023-02-27

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: University of Leeds
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-12-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Pioglitazone (drug)

Where the study takes place — 1 listed sites

Leeds Teaching Hospitals Trust
Leeds, West Yorkshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

ClinicalTrials.gov · NCT02244164 · Registry updated: 2023-02-16

Condition / research focus: Type 2 Diabetes; Incretinomimetics; Pancreas
Sponsor: Erasme University Hospital
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-10. Completion: 2023-02-13 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Incretinomimetics (drug) — also listed as: - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®).
DPP-4 inhibitors (drug) — also listed as: - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).

Where the study takes place — 1 listed sites

Gastroenterology Department Erasme Hospital
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT03948347 · Registry updated: 2023-02-06

Condition / research focus: Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus
Sponsor: First Affiliated Hospital of Jinan University
Countries with listed sites: China
Registry dates and results: Start: 2019-06-25. Completion: 2024-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

POSE2.0 With GLP-1 Agonist for Obesity Management

ClinicalTrials.gov · NCT05705388 · Registry updated: 2023-01-30

Condition / research focus: Obesity
Sponsor: Emirates Health Services (EHS)
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-01-16. Completion: 2026-01-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

POSE2.0 Endoscopic Gastric Remodeling (device)
Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Ibrahim Bin Hamad Obaidullah Hospital
Ras al-Khaimah, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

ClinicalTrials.gov · NCT05438186 · Registry updated: 2023-01-25

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2022-09-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

In-market Utilisation of Liraglutide Used for Weight Management in Europe

ClinicalTrials.gov · NCT02967757 · Registry updated: 2023-01-20

Condition / research focus: Metabolism and Nutrition Disorder; Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany · Italy
Registry dates and results: Start: 2016-12-22. Completion: 2019-05-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)

Where the study takes place — 19 listed sites

Novo Nordisk Investigational Site
Bad Nauheim, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Bünde, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Essen, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Hamburg, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kaiserslautern, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Mainz, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
München, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Münster, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Ulm, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Catania, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chieti, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cremona, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Novara, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pisa, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Potenza, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Roma, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Siena, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

ClinicalTrials.gov · NCT03172494 · Registry updated: 2022-12-14

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: China
Registry dates and results: Start: 2017-05-26. Completion: 2019-07-13 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin degludec/liraglutide (drug)
Insulin degludec (drug)
Liraglutide (drug)

Where the study takes place — 36 listed sites

Novo Nordisk Investigational Site
Hefei, Anhui, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cangzhou, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changzhou, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Zhenjiang, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanchang, Jiangxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changchun, Jilin, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Dalian, Liaoning, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Yinchuan, Ningxia, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Xi'an, Shaanxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Jinan, Shandong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pudong New District, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kunming, Yunnan, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

ClinicalTrials.gov · NCT03048578 · Registry updated: 2022-12-09

Condition / research focus: Obesity
Sponsor: NYU Langone Health
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-22. Completion: 2021-03-02 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug) — also listed as: Victoza
Placebo (drug)

Where the study takes place — 1 listed sites

New York University Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

ClinicalTrials.gov · NCT03479762 · Registry updated: 2022-11-25

Condition / research focus: Obesity; Overweight
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-04-20. Completion: 2022-09-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Soeborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

ClinicalTrials.gov · NCT05153590 · Registry updated: 2022-11-17

Condition / research focus: Obesity or Overweight
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2021-12-03. Completion: 2022-04-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda® (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Soeborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

ClinicalTrials.gov · NCT03799198 · Registry updated: 2022-11-14

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-07. Completion: 2020-05-22 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Weight Management Program (WMP) (other)
Medication for chronic weight management (Rx) (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

ClinicalTrials.gov · NCT05479591 · Registry updated: 2022-11-01

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: No country reported
Registry dates and results: Start: 2022-07-30. Completion: 2023-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IDegLira (drug) — also listed as: Xultophy

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Cardiovascular Effects of GLP-1 Receptor Activation

ClinicalTrials.gov · NCT03101930 · Registry updated: 2022-10-18

Condition / research focus: Obesity; PreDiabetes
Sponsor: Vanderbilt University Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-01. Completion: 2021-06-24 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Sitagliptin (drug)
hypocaloric diet (other)
Placebos (drug)
Exendin (9-39) (drug)

Where the study takes place — 1 listed sites

Vanderbilt University Medical Center
Nashville, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

ClinicalTrials.gov · NCT05492305 · Registry updated: 2022-09-26

Condition / research focus: Diabetes Mellitus; Obesity; Mental Health Issue
Sponsor: King's College London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-09. Completion: 2023-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 1 listed sites

Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

ClinicalTrials.gov · NCT05545800 · Registry updated: 2022-09-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Xiangya Hospital of Central South University
Countries with listed sites: China
Registry dates and results: Start: 2022-09-01. Completion: 2024-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

metformin+empagliflozin+insulin glargine (drug)
IDegLira (drug)
premixed insulin analogues (drug)

Where the study takes place — 1 listed sites

Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

ClinicalTrials.gov · NCT04903509 · Registry updated: 2022-08-31

Condition / research focus: Healthy
Sponsor: Boehringer Ingelheim
Countries with listed sites: Germany
Registry dates and results: Start: 2021-06-08. Completion: 2022-08-26 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BI 1820237 (drug)
Placebo (drug)
Saxenda® (drug) — also listed as: Liraglutide
Paracetamol-ratiopharm® (drug) — also listed as: Paracetamol

Where the study takes place — 1 listed sites

CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Liraglutide for HIV-associated Neurocognitive Disorder

ClinicalTrials.gov · NCT02743598 · Registry updated: 2022-07-29

Condition / research focus: HIV Infection; Diabetes Mellitus Type 2; Obesity; Overweight; Metabolic Syndrome
Sponsor: Temple University
Countries with listed sites: United States
Registry dates and results: Start: 2016-09. Completion: 2018-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Cherie Vaz
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT02344186 · Registry updated: 2022-07-29

Condition / research focus: Type 2 Diabetes
Sponsor: Temple University
Countries with listed sites: United States
Registry dates and results: Start: 2014-05. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza

Where the study takes place — 1 listed sites

Temple University Hospital
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 23:23 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT05467514 · Registry updated: 2023-03-02

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: David Sanchez Garcia
Countries with listed sites: Mexico
Registry dates and results: Start: 2022-07-01. Completion: 2023-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Centro Médico Nacional del Noreste Hospital de Especialidades UMAE 25
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study of LY3537021 in Healthy Participants

ClinicalTrials.gov · NCT05444569 · Registry updated: 2023-03-01

Condition / research focus: Healthy
Sponsor: Eli Lilly and Company
Countries with listed sites: Singapore
Registry dates and results: Start: 2022-08-08. Completion: 2023-02-24 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LY3537021 (drug)
Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT04657939 · Registry updated: 2023-02-27

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: University of Leeds
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-12-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Pioglitazone (drug)

Where the study takes place — 1 listed sites

Leeds Teaching Hospitals Trust
Leeds, West Yorkshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableTerminatedINTERVENTIONAL

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

ClinicalTrials.gov · NCT02244164 · Registry updated: 2023-02-16

Condition / research focus: Type 2 Diabetes; Incretinomimetics; Pancreas
Sponsor: Erasme University Hospital
Countries with listed sites: Belgium
Registry dates and results: Start: 2014-10. Completion: 2023-02-13 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Incretinomimetics (drug) — also listed as: - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®).
DPP-4 inhibitors (drug) — also listed as: - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®).

Where the study takes place — 1 listed sites

Gastroenterology Department Erasme Hospital
Brussels, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT03948347 · Registry updated: 2023-02-06

Condition / research focus: Ischemic Stroke; Transient Ischemic Attack; Type 2 Diabetes Mellitus
Sponsor: First Affiliated Hospital of Jinan University
Countries with listed sites: China
Registry dates and results: Start: 2019-06-25. Completion: 2024-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza

Where the study takes place — 1 listed sites

The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

POSE2.0 With GLP-1 Agonist for Obesity Management

ClinicalTrials.gov · NCT05705388 · Registry updated: 2023-01-30

Condition / research focus: Obesity
Sponsor: Emirates Health Services (EHS)
Countries with listed sites: United Arab Emirates
Registry dates and results: Start: 2023-01-16. Completion: 2026-01-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

POSE2.0 Endoscopic Gastric Remodeling (device)
Liraglutide injection (drug)

Where the study takes place — 1 listed sites

Ibrahim Bin Hamad Obaidullah Hospital
Ras al-Khaimah, United Arab Emirates
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

ClinicalTrials.gov · NCT05438186 · Registry updated: 2023-01-25

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2022-09-01. Completion: 2022-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

In-market Utilisation of Liraglutide Used for Weight Management in Europe

ClinicalTrials.gov · NCT02967757 · Registry updated: 2023-01-20

Condition / research focus: Metabolism and Nutrition Disorder; Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany · Italy
Registry dates and results: Start: 2016-12-22. Completion: 2019-05-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

liraglutide (drug)

Where the study takes place — 19 listed sites

Novo Nordisk Investigational Site
Bad Nauheim, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Bünde, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Essen, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Hamburg, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kaiserslautern, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Mainz, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
München, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Münster, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Ulm, Germany
Site recruitment: Not reported
Novo Nordisk Investigational Site
Catania, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chieti, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cremona, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Novara, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pisa, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Potenza, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Roma, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Rome, Italy
Site recruitment: Not reported
Novo Nordisk Investigational Site
Siena, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

ClinicalTrials.gov · NCT03172494 · Registry updated: 2022-12-14

Condition / research focus: Diabetes; Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: China
Registry dates and results: Start: 2017-05-26. Completion: 2019-07-13 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Insulin degludec/liraglutide (drug)
Insulin degludec (drug)
Liraglutide (drug)

Where the study takes place — 36 listed sites

Novo Nordisk Investigational Site
Hefei, Anhui, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, Fujian, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Cangzhou, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shijiazhuang, Hebei, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changzhou, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Huai'an, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanjing, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Zhenjiang, Jiangsu, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Nanchang, Jiangxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Changchun, Jilin, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Dalian, Liaoning, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Yinchuan, Ningxia, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Xi'an, Shaanxi, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Jinan, Shandong, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Pudong New District, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Tianjin, Tianjin Municipality, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Kunming, Yunnan, China
Site recruitment: Not reported
Novo Nordisk Investigational Site
Fuzhou, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

ClinicalTrials.gov · NCT03048578 · Registry updated: 2022-12-09

Condition / research focus: Obesity
Sponsor: NYU Langone Health
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-22. Completion: 2021-03-02 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda (drug) — also listed as: Victoza
Placebo (drug)

Where the study takes place — 1 listed sites

New York University Medical Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

ClinicalTrials.gov · NCT03479762 · Registry updated: 2022-11-25

Condition / research focus: Obesity; Overweight
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-04-20. Completion: 2022-09-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Soeborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

ClinicalTrials.gov · NCT05153590 · Registry updated: 2022-11-17

Condition / research focus: Obesity or Overweight
Sponsor: Novo Nordisk A/S
Countries with listed sites: Denmark
Registry dates and results: Start: 2021-12-03. Completion: 2022-04-15 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saxenda® (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Soeborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

ClinicalTrials.gov · NCT03799198 · Registry updated: 2022-11-14

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-07. Completion: 2020-05-22 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Weight Management Program (WMP) (other)
Medication for chronic weight management (Rx) (drug)

Where the study takes place — 1 listed sites

Novo Nordisk Investigational Site
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

ClinicalTrials.gov · NCT05479591 · Registry updated: 2022-11-01

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: No country reported
Registry dates and results: Start: 2022-07-30. Completion: 2023-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IDegLira (drug) — also listed as: Xultophy

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Cardiovascular Effects of GLP-1 Receptor Activation

ClinicalTrials.gov · NCT03101930 · Registry updated: 2022-10-18

Condition / research focus: Obesity; PreDiabetes
Sponsor: Vanderbilt University Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-01. Completion: 2021-06-24 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Sitagliptin (drug)
hypocaloric diet (other)
Placebos (drug)
Exendin (9-39) (drug)

Where the study takes place — 1 listed sites

Vanderbilt University Medical Center
Nashville, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

ClinicalTrials.gov · NCT05492305 · Registry updated: 2022-09-26

Condition / research focus: Diabetes Mellitus; Obesity; Mental Health Issue
Sponsor: King's College London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-09. Completion: 2023-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)

Where the study takes place — 1 listed sites

Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

ClinicalTrials.gov · NCT05545800 · Registry updated: 2022-09-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Xiangya Hospital of Central South University
Countries with listed sites: China
Registry dates and results: Start: 2022-09-01. Completion: 2024-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

metformin+empagliflozin+insulin glargine (drug)
IDegLira (drug)
premixed insulin analogues (drug)

Where the study takes place — 1 listed sites

Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

ClinicalTrials.gov · NCT04903509 · Registry updated: 2022-08-31

Condition / research focus: Healthy
Sponsor: Boehringer Ingelheim
Countries with listed sites: Germany
Registry dates and results: Start: 2021-06-08. Completion: 2022-08-26 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BI 1820237 (drug)
Placebo (drug)
Saxenda® (drug) — also listed as: Liraglutide
Paracetamol-ratiopharm® (drug) — also listed as: Paracetamol

Where the study takes place — 1 listed sites

CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Liraglutide for HIV-associated Neurocognitive Disorder

ClinicalTrials.gov · NCT02743598 · Registry updated: 2022-07-29

Condition / research focus: HIV Infection; Diabetes Mellitus Type 2; Obesity; Overweight; Metabolic Syndrome
Sponsor: Temple University
Countries with listed sites: United States
Registry dates and results: Start: 2016-09. Completion: 2018-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)

Where the study takes place — 1 listed sites

Cherie Vaz
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT02344186 · Registry updated: 2022-07-29

Condition / research focus: Type 2 Diabetes
Sponsor: Temple University
Countries with listed sites: United States
Registry dates and results: Start: 2014-05. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Victoza

Where the study takes place — 1 listed sites

Temple University Hospital
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →